Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q75T13
UPID:
PGAP1_HUMAN
Alternative names:
Post-GPI attachment to proteins factor 1
Alternative UPACC:
Q75T13; Q4G0R8; Q4ZG47; Q53SM0; Q6AW92; Q6UWV4; Q9HA24
Background:
GPI inositol-deacylase, also known as Post-GPI attachment to proteins factor 1, plays a crucial role in the inositol deacylation of GPI-anchored proteins. This process is vital for the efficient transport of these proteins from the endoplasmic reticulum to the Golgi apparatus. The protein's function underscores its importance in cellular transport mechanisms.
Therapeutic significance:
GPI inositol-deacylase is linked to a neurodevelopmental disorder characterized by dysmorphic features, spasticity, and brain abnormalities. Understanding the role of GPI inositol-deacylase could open doors to potential therapeutic strategies for this disorder, highlighting the protein's significance in medical research.